Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Mol Cancer Res. 2010 Jun 22;8(7):986–993. doi: 10.1158/1541-7786.MCR-10-0154

Figure 4.

Figure 4

A. BaF3/FLT3/ITD cells were treated with CDDO-Me and PKC412 at various concentrations, alone or in combination, for the indicated times. Total cell lysates were analyzed by immunoblotting with anti-PARP or anti-Actin antibodies. B. BaF3/FLT3/ITD cells were treated with CDDO-Me and PKC412 and total cell lysates were analyzed by immunoblotting with anti-Caspase-3 or anti-Actin antibodies. C. MOLM-14 cells were treated with CDDO-Me and PKC412 at various concentrations, alone or in combination, for 48 hours. Total cell lysates were analyzed by immunoblotting with anti-PARP or anti-Actin antibodies.